Get the Stockscreener App
920.63
1.71%
15.47
Pre-market:
919.10
-1.53
-0.17%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $920.63, with a volume of 3.92M.
It is up +1.71% in the last 24 hours and up +13.51% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
See More
Previous Close:
$905.16
Open:
$901.84
24h Volume:
3.92M
Relative Volume:
1.16
Market Cap:
$874.97B
Revenue:
$45.04B
Net Income/Loss:
$10.59B
P/E Ratio:
78.62
EPS:
11.71
Net Cash Flow:
$414.30M
1W Performance:
+5.37%
1M Performance:
+13.51%
6M Performance:
-4.10%
1Y Performance:
+22.15%
1-Day Range:
$892.61
$921.22
1-Week Range:
$870.02
$925.50
52-Week Range:
$711.40
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
920.63 | 874.97B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
90.65 | 402.40B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
209.03 | 369.01B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
165.02 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
92.25 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Where Will Eli Lilly Be in 5 Years? - MSN
Lilly attracted to molecular glue space via deal with Magnet - The Pharma Letter
Jim Cramer on Eli Lilly and Company (LLY): ‘Eli Lilly Cutting The Price Is Gonna Make It So That It Is Dramatically Good’ - Insider Monkey
Eli Lilly Lowers Cost of Zepbound Vials to Attract People Without Insurance Coverage - Verywell Health
Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology - BioWorld Online
Eli Lilly comes for knockoff weight loss drugs in new ad campaign - Quartz
Eli Lilly takes aim at weight-loss drug copies with new ad campaign - Reuters
Eli Lilly will build 4 new manufacturing sites to increase domestic drug production - IndyStar
Mounjaro Maker Eli Lilly Swipes at Unapproved GLP-1 Rivals in Oscars Ad - NewsBreak
Verve Can Shrug Off Vertex Loss But Lilly Opt-In Is Crucial - Insights
Lilly to participate in Leerink Partners Global Healthcare Conference - Quantisnow
Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target (CORRECTED) - Benzinga
Is Eli Lilly Stock A Buy As It Plays Ball With Trump To The Tune Of $27 Billion? - Investor's Business Daily
Bernstein reiterates Eli Lilly stock Outperform rating, $1100 target - Investing.com India
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor - Quantisnow
Eli Lilly in pact with Magnet Bio to develop cancer drugs in a deal worth up to $1.25B - Seeking Alpha
Eli Lilly's big investment, cheaper Zepbound, and what's next for Hims & Hers: Pharma news roundup - Quartz
Friday Five – Lilly expands while coming for compounders, SERD surges, flu vaccines under fire…and more - FirstWord Pharma
Imagine Entertainment and MACRO Partner With Eli Lilly and Company to Bolster Film and TV Representation of Health Conditions - AOL
Top Research Reports for Amazon, Eli Lilly & S&P Global - Yahoo Finance
LLY Stock Quote Price and Forecast - CNN
Lilly Plans to More than Double U.S. Manufacturing Investment Since 2020 Exceeding $50 Billion - Genetic Engineering & Biotechnology News
Imagine, MACRO Partner With Eli Lilly for Better Health Condition Representation - Variety
Eli Lilly wants to make drugs in America. First it wants a tax cut - Quartz
Eli Lilly investing $27B more in US manufacturing - Fox Business
Roundup: Eli Lilly expansion / WARN notices / US jobless claims rise - Greater Baton Rouge Business Report
Eli Lilly expands US manufacturing build-out with $50B target - Construction Dive
Eli Lilly to spend $27B on four new manufacturing sites - Daily Journal
Lilly to Invest $27B in 4 New US Manufacturing Plants - Powder Bulk Solids
Indy-based pharmaceutical giant Eli Lilly to invest roughly $27 billion in manufacturing - WFYI
Eli Lilly unveils plan for four U.S. "mega-sites" - Axios
Eli Lilly says it will spend billions to move drug manufacturing to U.S. soil - The Washington Post
Eli Lilly Latest US Company to Commit to Domestic Investments - MSN
Eli Lilly CEO on $27 billion investment in U.S. manufacturing expansion - MSN
Major Shareholder Sells Massive Chunk of Eli Lilly Stock! - TipRanks
Eli Lilly and Co. Plans to Build Four New Sites in the U.S.WIBC - WIBC - Indianapolis News & Politics
News | Eli Lilly raises cost of planned US manufacturing expansion to $50 billion - CoStar Group
Lilly to Spend $27 Billion to Bolster US Drug Manufacturing - MSN
Eli Lilly plans $27bn in new plants as Trump threatens pharma tariffs - MSN
Lilly plans major expansion manufacturing capabilities in the U.S. - NewsBreak
Eli Lilly plans to invest $27B to build four new US plants as tariffs loom - NewsBreak
Lilly Endowment Inc sells $203 million in Eli Lilly stock - Investing.com
Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target - AOL
Lilly CEO wields manufacturing plans to push pharma-friendly policies - BioPharma Dive
Eli Lilly plans to more than double investment in US manufacturing - WTHR
Lilly to build new pharmaceutical sites, bring ‘high-wage’ jobs - FOX 59 Indianapolis
Eli Lilly announces $27-billion US expansion: To add 13,000 jobs and new manufacturing sites - The Economic Times
Organovo Sells FXR IP for $10 Million in New Deal with Eli Lilly - 3D Printing Industry
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments - MSN
Pharma giant with heavy North Carolina presence charts $27B expansion, thousands of new jobs - The Business Journals
Lilly plans to invest $27 billion in new US plants as Trump threatens pharmaceutical tariffs - MSN
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):